Zika Virus. Centers for Disease Control and Prevention

Transcription

1 Centers for Disease Control and Prevention Zika Virus Ingrid Rabe Medical Epidemiologist Arboviral Diseases Branch Centers for Disease Control and Prevention February 1, 2016

2 Zika Virus Single stranded RNA virus Genus Flavivirus, family Flaviviridae Closely related to dengue, yellow fever, Japanese encephalitis, and West Nile viruses Transmitted to humans primarily by Aedes (Stegomyia) species mosquitoes

3 Zika Virus Vectors: Aedes Mosquitoes Aedes (stegomyia) species mosquitoes Ae. aegypti more efficient vectors for humans Ae. albopictus Also transmit dengue and chikungunya viruses Lay eggs in domestic water-holding containers Live in and around households Aggressive daytime biters; can also bite at night

4 Aedes aegypti and Aedes albopictus Mosquitoes: Geographic Distribution in the United States Aedes aegypti Aedes albopictus

5 Zika Virus Transmission Cycles Sylvatic (jungle) cycle Epidemic (urban) cycle

6 Other Modes of Transmission Maternal-fetal Intrauterine Perinatal Other Sexual Blood transfusion Laboratory exposure Theoretical Organ or tissue transplantation Breast milk

7 Zika Virus: Countries and Territories with Active Zika Virus Transmission as of February 2, Updated regulary

8 Zika Virus Epidemiology First isolated from a monkey in Uganda in 1947 Prior to 2007, only sporadic human disease cases reported from Africa and southeast Asia In 2007, first outbreak reported on Yap Island, Federated States of Micronesia In , >28,000 suspected cases reported from French Polynesia* *

9 Zika Virus in the Americas In May 2015, the first locally-acquired cases in the Americas were reported in Brazil Currently, outbreaks are occurring in many countries or territories in the Americas, including the Commonwealth of Puerto Rico and the U.S. Virgin Islands Spread to other countries likely

10 Zika Virus in the Continental United States Local vector-borne transmission of Zika virus has not been reported in the continental United States Since 2011, there have been laboratory-confirmed Zika virus cases identified in travelers returning from areas with local transmission With current outbreaks in the Americas, cases among U.S. travelers will most likely increase Imported cases may result in virus introduction and local spread in some areas of U.S.

11 Zika Virus Incidence and Attack Rates Infection rate: 73% (95% CI 68 77) Symptomatic attack rate among infected: 18% (95% CI 10 27) All age groups affected Adults more likely to present for medical care No severe disease, hospitalizations, or deaths Note: Rates based on serosurvey on Yap Island, 2007 (population 7,391) Duffy M. N Engl J Med 2009

12 Reported Clinical Symptoms Among Confirmed Zika Virus Disease Cases Symptoms N (n=31) Macular or papular rash 28 90% Subjective fever 20 65% Arthralgia 20 65% Conjunctivitis 17 55% Myalgia 15 48% Headache 14 45% Retro-orbital pain 12 39% Edema 6 19% Vomiting 3 10% % Yap Island, 2007 Duffy M. N Engl J Med 2009

13 Zika Virus Clinical Disease Course and Outcomes Clinical illness usually mild Symptoms last several days to a week Severe disease requiring hospitalization uncommon Fatalities are rare Guillain-Barré syndrome reported in patients following suspected Zika virus infection Relationship to Zika virus infection is not known

14 Zika Virus and Microcephaly in Brazil Reports of a substantial increase in number of babies born with microcephaly in 2015 in Brazil; true baseline unknown Zika virus infection identified in several infants born with microcephaly (including deaths) and in early fetal losses Zika virus detected prenatally in amniotic fluid from two pregnant women ( 30 weeks gestation) with fetal microcephaly and intracranial calcifications detected on ultrasound Some of the infants with microcephaly have tested negative for Zika virus Incidence of microcephaly among fetuses with congenital Zika infection is unknown

15 Rates of Microcephaly Over Time: the Americas and the Caribbean Comparison of the rates of microcephaly in the Americas and Caribbean from and 2015 Updated as of Epidemiological Week 52 (December 27, 2015 January 2, 2016) Microcephaly rates by state in Brazil (cases per 1,000 live births) Countries Countries with Zika confirmed cases Epi Week Country limits Brazil State Boundaries Data Source: Reported from the IHR National Focal Points and through the Ministry of Health websites. Map Production: PAHO-WHO AD CHA IR ARO Source: Pan American Health Organization, Epidemiological update, 17 January 2016

16 Distinguishing Zika from Dengue and Chikungunya Dengue and chikungunya viruses transmitted by same mosquitoes with similar ecology Dengue and chikungunya can circulate in same area and rarely cause coinfections Diseases have similar clinical features Important to rule out dengue, as proper clinical management can improve outcome* *WHO dengue clinical management guidelines:

17 Clinical Features: Zika Virus Compared to Dengue and Chikungunya Features Zika Dengue Chikungunya Fever Rash Conjunctivitis Arthralgia Myalgia Headache Hemorrhage Shock - + -

18 Diagnostic Testing for Zika Virus Reverse transcriptase-polymerase chain reaction (RT-PCR) for viral RNA in serum collected 7 days after illness onset Serology for IgM and neutralizing antibodies in serum collected 4 days after illness onset Plaque reduction neutralization test (PRNT) for 4-fold rise in virus-specific neutralizing antibodies in paired sera Immunohistochemical (IHC) staining for viral antigens or RT-PCR on fixed tissues

19 Serology Cross-Reactions with Other Flaviviruses Zika virus serology (IgM) can be positive due to antibodies against related flaviviruses (e.g., dengue and yellow fever viruses) Neutralizing antibody testing may discriminate between cross-reacting antibodies in primary flavivirus infections Difficult to distinguish infecting virus in people previously infected with or vaccinated against a related flavivirus Healthcare providers should work with state and local health departments to ensure test results are interpreted correctly

20 Laboratories for Diagnostic Testing No commercially-available diagnostic tests Testing performed at CDC and a few state health departments CDC is working to expand laboratory diagnostic testing in states Healthcare providers should contact their state health department to facilitate diagnostic testing

21 Initial Assessment and Treatment No specific antiviral therapy Treatment is supportive (i.e., rest, fluids, analgesics, antipyretics) Suspected Zika virus infections should be evaluated and managed for possible dengue or chikungunya virus infections Aspirin and other NSAIDs should be avoided until dengue can be ruled out to reduce the risk of hemorrhage

22 Differential Diagnosis for Zika Virus Disease Dengue Chikungunya Leptospirosis Malaria Rickettsia Group A streptococcus Rubella Measles Adenovirus Enterovirus Parvovirus * Similar clinical features

23 Zika Virus Disease Surveillance Consider in travelers with acute onset of fever, maculopapular rash, arthralgia, or conjunctivitis within 2 weeks after return Inform and evaluate women who traveled to areas with Zika virus transmission while they were pregnant Evaluate fetuses/infants of women infected during pregnancy for possible congenital infection and microcephaly Be aware of possible local transmission in areas where Aedes species mosquitoes are active

24 Reporting Zika Virus Disease Cases As an arboviral disease, Zika virus disease is a nationally notifiable disease Healthcare providers encouraged to report suspected cases to their state health department State health departments are requested to report laboratory-confirmed cases to CDC Timely reporting allows health departments to assess and reduce the risk of local transmission or mitigate further spread

25 Zika Virus Preventive Measures No vaccine or medication to prevent infection or disease Primary prevention measure is to reduce mosquito exposure Pregnant women should consider postponing travel to areas with ongoing Zika virus outbreaks Protect infected people from mosquito exposure during first week of illness to prevent further transmission

26 Possible Future Course of Zika Virus in the Americas Virus will continue to spread in areas with competent vectors Transmission increasing in Central America, Mexico, and Caribbean Anticipate further spread in the Commonwealth of Puerto Rico and U.S. Virgin Islands Travel-associated cases introduce virus to U.S. states Imported cases will result in some local transmission and outbreaks Air conditioning may limit the size and scope of outbreaks Colder temperatures will interrupt and possibly stop further spread Experience from dengue might be predictive From , 1.5 million dengue cases reported per year to PAHO 558 travel-related and 25 locally transmitted cases in U.S. states

27 Zika Virus Remaining Questions Incidence of maternal- fetal transmission by trimester Factors that influence (e.g., severity of infection, maternal immune response) Risk of microcephaly and other fetal and neonatal outcomes Risk of Guillain-Barré syndrome Potential for long-term reservoirs of Zika

28 CDC Guidance - published Interim Guidelines for the Evaluation and Testing of Infants with Possible Congenital Zika Virus Infection United States, 2016 (Jan 29, 2016) Interim Guidelines for Pregnant Women During a Zika Virus Outbreak United States, 2016 (Jan 22, 2016) HAN: Recognizing, Managing, and Reporting Zika Virus Infections in Travelers Returning from Central America, South America, the Caribbean, and Mexico (Jan 15, 2016) Travel health notices (continually updating)

29 CDC Guidance - soon to be released Interim guidance for women of reproductive age in areas with local transmission of Zika virus Interim guidance for Zika virus disease case investigation, diagnosis, and response for U.S. state and territorial health departments Procedures following different scenarios Case data collection form Draft case definitions and classifications Diagnostic testing

30 CDC Activities Coordinate response with PAHO and other regional partners Assist with investigations of microcephaly and Guillain-Barré syndrome Continue to evaluate and revise guidance as new data emerge Distribute guidance through health notices, MMWR publications and the CDC website Communicate regularly with clinicians (e.g., COCA calls), professional organizations and state and local partners

31 Additional resources CDC Zika virus information: PAHO Zika virus pages: =427&Itemid=41484&lang=en Zika virus information for clinicians: Zika virus information for travelers and travel health providers: Travel notices:

32 Selected references Besnard M, et al. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February Euro Surveill 2014;19(13): Duffy MR, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009;360: Foy BD, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 2011;17(5): Hayes EB. Zika virus outside Africa. Emerg Infect Dis 2009;15(9) Kusana S, et al. Two cases of Zika fever imported from French Polynesia to Japan, December to January Euro Surveill 2014;19(4): Kwong JC, et al. Case report: Zika virus infection acquired during brief travel to Indonesia. Am J Trop Med Hyg 2013;89(3): Lanciotti RS, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, Emerg Infect Dis 2008;14(8): Musso D, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February Euro Surveill 2014;19(14): Oehler E, et al. Zika virus infection complicated by Guillain-Barre syndrome case report, French Polynesia, December Euro Surveill 2014;19(9): Tappe D, et al. First case of laboratory-confirmed Zika virus infection imported into Europe, November Euro Surveill 2014;19(4):20685.

33 Thank you For more information, contact CDC CDC-INFO ( ) TTY: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.